IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4091
Positioning
Market Dominance
Manufacturing
Medical Equipment
$2M
Charles J. Fisher
Aethlon Medical, Inc. focuses on developing products to diagnose and treat life and organ threatening diseases. The company was founded in 1999 and is based in San Diego, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AEMD AETHLON MEDICAL INC | 35 | 21 | 22 | 60 | - | - | -132.3% | -110.3% | - | -5671.4% | -5571.4% | - | 0.0% | 20.0x | $2M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
AETHLON MEDICAL INC (AEMD) receives a "Avoid" rating with a composite score of 35.2/100. It ranks #4091 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for AEMD.
View All RatingsROE proxy -132.3% (sector -1.9%)
GM N/A vs sector 44%, OM -5671% vs sector 3%
Capital turnover N/A, R&D intensity 1241.9%
Rev growth N/A, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate AETHLON MEDICAL INC (AEMD) as Avoid with a composite score of 35.2/100 at a current price of $2.05. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
AETHLON MEDICAL INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.2/100 places it at rank #4091 in our full universe.
No Moat
Very High
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
AETHLON MEDICAL INC represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags AETHLON MEDICAL INC with an Avoid rating, assigning a composite score of 35.2/100 and 1 out of 5 stars. Ranked #4091 of 7,333 stocks, AEMD falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
AETHLON MEDICAL INC registers a weak quality score of just 21/100, indicating significant profitability challenges. The company reports a return on equity of -132.3% (sector avg: -1.9%), net margins of -5571.4% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
AEMD registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.39x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
AETHLON MEDICAL INC's investment score of 34/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -110.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
AEMD demonstrates moderate momentum with a score of 60/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 3.27 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
AETHLON MEDICAL INC registers a low stability score of 13/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 3.27 and a debt-to-equity ratio of 20.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 51/100 for AEMD suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 3.27), elevated leverage (D/E: 20.00x), micro-cap liquidity risk. With a $2M market cap (micro-cap), AETHLON MEDICAL INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
AETHLON MEDICAL INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4091 of 7,333 overall (44th percentile). Key comparisons include ROE of -132.3% trailing the -1.9% sector median and operating margins of -5671.4% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While AEMD currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (13) would have the largest impact on the composite score.
ROE 6865% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 226053% BELOW SECTOR MEDIAN
Debt/Equity 9424% ABOVE SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 participants being treated, with queue building for patient participation in trial Aethlon Medical (NASDAQ:AEMD) announced FY 3Q (quarter ended December 31, 2025) results and provided a business update last week. The company’s primary focus is on researching lead asset, the Hemopurifier® therapeutic blood filtration system, as a
Operator: Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2026 Earnings and Corporate Update Conference Call. [Operator Instructions] Please note that this event is being recorded.
Aethlon Medical (AEMD) Q3 2026 earnings call: Hemopurifier oncology trial progress, costs, and late-March safety review.
Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing the Hemopurifier device for cancer and infectious disease treatment, announced it will release fiscal Q3 2025 financial results on February 12, 2026, at 4:15 p.m. ET, followed by a management conference call at 4:30 p.m. ET. The Hemopurifier has received FDA Breakthrough Device designations for advanced/metastatic cancer and life-threatening viral infections.